Wealthspire Advisors LLC Makes New $219,000 Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Wealthspire Advisors LLC bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,622 shares of the biopharmaceutical company's stock, valued at approximately $219,000.

A number of other hedge funds have also added to or reduced their stakes in ITCI. True Wealth Design LLC bought a new position in shares of Intra-Cellular Therapies in the third quarter valued at approximately $32,000. GAMMA Investing LLC lifted its stake in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Capital Performance Advisors LLP bought a new position in Intra-Cellular Therapies in the 3rd quarter valued at $74,000. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 4th quarter valued at $96,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Intra-Cellular Therapies in the third quarter worth $97,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Trading Up 2.4 %

Shares of NASDAQ:ITCI traded up $3.06 on Monday, reaching $131.26. 6,934,256 shares of the company traded hands, compared to its average volume of 3,911,540. Intra-Cellular Therapies, Inc. has a 52 week low of $63.30 and a 52 week high of $131.35. The business's 50-day simple moving average is $114.58 and its 200 day simple moving average is $91.72. The stock has a market capitalization of $13.96 billion, a P/E ratio of -150.87 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Baird R W downgraded shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Piper Sandler reissued a "neutral" rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their price target for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.